Preclinical Characterization of Naturally Occurring Polyketide Cyclophilin Inhibitors from the Sanglifehrin FamilyMatthew A. Gregory, Barrie Wilkinson, Mahmood Piraee et al.|Antimicrobial Agents and Chemotherapy|2011Cited by 54
Bioengineering and Semisynthesis of an Optimized Cyclophilin Inhibitor for Treatment of Chronic Viral InfectionMagnus J. Hansson, Matthew A. Gregory, Steven J. Moss et al.|Chemistry & Biology|2015Cited by 38
Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infectionSteven J. Moss, Matthew A. Gregory, Michael Bobardt et al.|MedChemComm|2011Cited by 26
Activity of Novel Cyclophilin Inhibitors based on the Polyketide, Sanglifehrin A, against HIVMichael Bobardt, Matthew A. Gregory, Steven J. Moss et al.|Antiviral Research|2011Cited by 2
841 BC556, A POTENT, PAN-GENOTYPIC, HIGH BARRIER TO RESISTANCE, SECOND GENERATION CYCLOPHILIN INHIBITOR FOR TREATMENT OF CHRONIC HCV INFECTIONSteven J. Moss, Matthew A. Gregory, Javier García-Rivera et al.|Journal of Hepatology|2012Cited by 2